Actively Recruiting
KARU-FERTIL: Chlordecone Exposure and Female Fertility Study in Women Consulting for Infertility
Led by Centre Hospitalier Universitaire de la Guadeloupe · Updated on 2025-11-17
634
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
Sponsors
C
Centre Hospitalier Universitaire de la Guadeloupe
Lead Sponsor
I
Institut Pasteur de Guadeloupe
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating the possible link between exposure to chlordecone, a persistent organochlorine pesticide formerly used in the French West Indies, and female fertility. This study focuses on women who are consulting for couple infertility in Guadeloupe. Chlordecone has known estrogenic and progestagenic effects and has been shown in animal studies to impair ovulation and reduce ovarian reserve, but its impact on human female fertility has not been studied before. This observational study will measure levels of anti-mullerian hormone (AMH), a marker of ovarian reserve, and analyze their association with different levels of chlordecone exposure. Additional assessments will include counting antral follicles within the menstrual cycle and evaluating other environmental exposures, including persistent organic pollutants. The study will also examine the relationship between chlordecone exposure and the risk of main causes of female infertility, as well as outcomes after assisted reproductive technology treatments over a two-year period. Participants will undergo AMH measurement during their assisted reproductive technology assessment and have antral follicle counts done between days 2 and 4 of their spontaneous menstrual cycle. Researchers will collect baseline exposure data and follow participants for up to two years to monitor fertility treatment outcomes. This study will help clarify how environmental factors like chlordecone and the vaginal and endometrial microbiome might affect female fertility in this population.
CONDITIONS
Brief Title
Chlordecone Exposure and Female Fertility
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged from 18 to 39 years
- Consulting for couple infertility at the Caribbean Center for Reproductive Medicine of the University Hospital of Guadeloupe
- Provided free, informed, and written consent
You will not qualify if you...
- Women who do not meet the inclusion criteria
- Lack of free, informed, and written consent
- Not consulting for couple infertility at the designated center
- Outside the age range of 18 to 39 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Baseline
Participants undergo assessments including measurement of AMH levels and antral follicle count to evaluate fertility and exposure to chlordecone and other pollutants.
1 visit (in-person)
Duration - Up to 2 years after baseline
Participants are monitored to assess changes in chlordecone levels and fertility outcomes over time, including during assisted reproductive technology management.
Follow-up visits as scheduled during 2 years
Trial Site Locations
Total: 1 location
1
Chu de La Guadeloupe
Pointe-à-Pitre, Guadeloupe, 97159
Actively Recruiting
Research Team
M
Mélanie petapermal
V
Valérie Hamony Soter
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here